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Objectives This study sought to quantify the incremental cost-effectiveness ratios (ICER) of angiotensin-converting enzyme
inhibitor (ACEI), beta-blocker (BB), and aldosterone antagonist (AldA) therapies for patients with heart failure
with reduced ejection fraction (HFrEF).
Background There are evidence-based, guideline-directed medical therapies for patients with HFrEF, but the incremental cost-
effectiveness of these therapies has not been well studied using contemporary data.
Methods A Markov model with lifetime horizon and two states, dead or alive, was created. We compared HFrEF patients
treated with diuretic agents alone to three treatment arms: 1) ACEI therapy alone; 2) ACEIBB; and 3)
ACEIBBAldA. Sequential therapy was also analyzed. HF hospitalizations and mortality rates were based on
representative studies. Costs of medications and inpatient and outpatient care were accounted for.
Results Treatment with ACEI and ACEIBB strictly dominated treatment with diuretics only (cost-saving). The greatest
gains in quality-adjusted life-years occurred when all 3 guideline-directed medications were provided. The incre-
mental cost-effectiveness ratio (ICER) of ACEIBBAldA versus ACEIBB and ACEIBB versus ACEI was
$1,500 per quality-adjusted life-year. The cost-savings in the ACEI and ACEIBB cohorts compared to that with
diuretics alone were $444 and $33, respectively. Assuming lower treatment costs and lower hospitalization
rates in the ACEIBBAldA arm resulted in greater cost-savings. Even in the most unfavorable situations, the
ICER was $10,000 per life-year gained.
Conclusions Our analysis demonstrates that medical treatment of HFrEF is highly cost-effective and may even result in cost-
savings. Greater efforts to ensure optimal adherence to guideline-directed medical therapy for HFrEF are
warranted. (J Am Coll Cardiol 2013;61:1440–6) © 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.12.022H
cHeart failure (HF) remains one of the leading causes of
mortality, morbidity, and health care-associated costs
worldwide. Approximately 6 million Americans have HF,
and the lifetime risk of developing HF is 1 in 5 (1,2). After
a HF hospitalization, 5-year mortality for HF is over 40%
(3,4). There are also substantial costs associated with HF,
including over 1 million HF admissions a year and $39.2
billion a year from direct and indirect costs (5).
Over the past 2 decades, there have been remarkable
advances in medical therapy for HF with reduced ejection
fraction (HFrEF). The use of angiotensin-converting en-
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2012, accepted December 17, 2012.zyme inhibitors (ACEI), beta-blockers (BB), and aldoste-
rone antagonists (AldA) has resulted in substantial reduc-
tions in mortality, morbidity, and hospitalizations in
HFrEF patients (6–8). Previous studies conducted when
these medications were available only as branded therapies
have shown that the cost-effectiveness of these therapies in
patients with mild to moderate HFrEF were $100 to
$25,000 per quality-adjusted life-year (QALY) compared to
that with conventional treatment (9–13).
However, now that ACEI, BB, and AldA have generic
formulations available, we hypothesized that guideline-
directed medical therapies for HFrEF will be of even greater
value and possibly cost-saving. In addition, the incremental
cost-effectiveness for each therapy has not been previously
evaluated using contemporary data, including costs associ-
ated with generic formulations and use of AldA plus BB
plus ACEI (AldABBACEI) therapy in chronic
FrEF. Our objective was to quantify the incremental
ost-effectiveness of ACEI, BB, and AldA therapies and the
ost-effectiveness of these therapies compared to that with
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erate HFrEF.
Methods
Markov models are commonly used to understand cost-
effectiveness of therapies in chronic diseases. We created a
Markov model to simulate costs, QALYs, and incremental
cost-effectiveness of patients with HFrEF receiving ACEI,
BB, and AldA in a cohort of hypothetical patients with mild
to moderate (New York Heart Association [NYHA] class II
or III) HF. Our model had a lifetime horizon, was U.S.
based, and consisted of two states: dead or alive. We
attempted to take the perspective of a lifetime single-payer/
vertically integrated healthcare system providing full cover-
age for hospitalizations, office visits, laboratory tests, med-
ications, and resources to the extent possible with available
cost data. The length of follow-up in the representative
studies of medical treatment for HF ranged from 12 to 41
months. We conservatively assumed that benefits for the
medical therapies lasted 2 years but that the costs of
treatment continued indefinitely. From year 3 until death,
the cohort reverted to having the same mortality and
hospitalization rates as the cohort receiving only diuretic
agents. We factored in the additional mortality seen with
increasing age based on U.S. lifetime tables (14). All costs
and QALYs were discounted at 3% and were in 2012 U.S.
dollars.
The placebo arm of the SOLVD (Study of Left Ventric-
ular Dysfunction), a large trial that has been used as the
basis for disease estimates by other studies, served as the
base (diuretic-only cohort) population in this study (6).
Patients included in this trial were HF patients with ejection
fractions of 35% or less and were treated with oral loop
diuretics. The mean age of patients in this study was 61
years of age, and 90% were in NYHA functional class II or
III. This group of patients represents the overall population
of patients in our cohort, defining “baseline” risk in this
study. We compared our baseline cohort (treatment with
diuretic-only cohort) to those in three treatment arms: patients
receiving: 1) ACEI; 2) ACEIBB; or 3) ACEIBBAldA
herapy. We also compared each incremental therapy to the
revious therapy: 1) ACEIBB versus ACEI; and 2) ACEI
BAldA versus ACEIBB therapy.
ospitalizations. Probabilities of hospitalization for the
aseline and ACEI cohorts were derived from the SOLVD,
s that study was the most representative of outcomes for
atients in our diuretic-only and ACEI cohorts (6). Total
umber of hospitalizations for HF at the end of the trial was
ivided by the number of people in each arm and the
verage follow-up (41 months) to estimate the yearly prob-
bility of hospitalization per person. The difference in
eaths or hospitalizations between the 2 groups did not
onverge at the end of the trial (41 months), but we
onservatively assumed that this decrease in hospitalization
as only in the first 2 years of our model.We derived the yearly proba-
ility of HF hospitalization for
he ACEIBB group by multi-
lying the yearly probability of
F hospitalization for the ACEI
roup by “1  x, x  the relative
isk reduction for HF hospitaliza-
ion” in the MERIT-CHF (Meto-
rolol CR/XL Randomised Inter-
ention Trial in Congestive Heart
ailure) study (relative risk reduc-
ion: 31.6%), a study representative
f the effects of BBACEI on
FrEF (7). We then derived the
early probability of HF hospital-
zations for the ACEIBB
ldA cohort from the EMPHASIS-HF (Eplerenone in Mild
atients Hospitalization and Survival Study in Heart Failure)
rial, a study representative of the effects of ACEIBBAldA
n HFrEF (8). That study showed a hazard ratio of 58% for
F hospitalizations for patients taking ACEIBBAldA
ompared to those taking ACEIBB. The hazard ratio
rom this study was calculated with a median follow-up of
1 months (we assumed this was equivalent to 24 months),
o we calculated the yearly hazard ratio by taking the square
oot of the 2-year hazard ratio (i.e.,x  1 year hazard
atio, x  2 year hazard ratio). We then multiplied the
yearly hazard ratio by the probability of HF hospitalizations
in the ACEIBB cohort. In both the EMPHASIS-HF
and MERIT-HF trials, the event curves for deaths and
HF hospitalizations continued to diverge at the end of
follow-up (average of 21 and 12 months, respectively)
(Table 1).
Costs. The costs taken into account in our model included
HF-related hospitalization, medications and medication
monitoring, and ambulatory care (Table 2). The average
cost of one inpatient hospitalization, based on the report by
Delea et al. (15), was multiplied by the probability of
hospitalization each year (as derived above) to obtain the
average yearly cost attributed to inpatient hospitalization per
patient. The probability of hospitalization accounted for
some patients requiring multiple hospitalizations in 1 year.
We conservatively assumed that the benefits for the medical
therapies lasted 2 years but that the costs of treatment
continued until death. The cost of ambulatory care was
based on the ambulatory care in the SOLVD trial (9). The
costs of medications were based on the prices of 30-day
prescriptions for generic medications (16). For base our
models, we excluded the costs of non-HF hospitalizations.
Based on our clinical experience, we assumed that the ACEI
and ACEIBB cohorts required four basic metabolic panel
tests and that the ACEIBBAldA cohort required six
basic metabolic panel tests in the first year. We assumed
that our base cohort and all cohorts after year 2 required
Abbreviations
and Acronyms
ACEI  angiotensin-
converting enzyme inhibitor
AldA  aldosterone
antagonists
BB  beta-blocker
HF  heart failure
HFrEF  heart failure with
reduced ejection fraction
ICER  incremental cost-
effectiveness ratio
QALY  quality-adjusted
life-yearthree metabolic panels a year because of diuretic use. The
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Centers for Medicare and Medicaid Services (CMS) reim-
bursement (17). All costs were in 2012 dollars and calcu-
lated using a consumer price index calculator (18). The
overall average cost for 1 year in each cohort was then
multiplied by the percentage of people alive in each cohort
to obtain a weighted average cost for the subjects alive in
each cohort (Table 2).
Mortality. We calculated the annual probability of death
for the baseline and ACEI cohort by calculating the
percentage of subjects alive at the end of the SOLVD trial
and then derived the annual probability of surviving (x 
probability of surviving to 4 years, 4x  probability of
urviving to 1 year) (6). We assumed the probability of
eath for the ACEI cohort was constant between years 1
nd 2 of the model. The probability of death in the
CEIBB cohort was derived from the MERIT-HF
tudy, which showed a 32% relative risk reduction in death
7). We multiplied the annual probability of death in the
CEI group by 1  x, x  relative risk reduction of
ortality from the MERIT-CHF study to derive annual
robability of death in the ACEIBB cohort. We derived
he annual probability of death for the ACEIBBAldA
ohort from the EMPHASIS-HF trial. That study showed
hazard ratio of 0.76 for patients receiving ACEI
BAldA therapy compared to those receiving ACEIBB
herapy (8). The hazard ratio from this study was calculated
ith a median follow-up of 21 months (we assumed this was
quivalent to 24 months), so we calculated the yearly hazard
atio by taking the square root of the 2-year hazard ratio
i.e.,x  1 year hazard ratio, x  2 year hazard ratio).
e then multiplied the yearly hazard ratio by the annual
robability of death in the ACEIBB cohort. The survival
urves in both the EMPHASIS-HF and MERIT-HF trials
ontinued to diverge at the end of trials, so we assumed that
he mortality rates were constant between years 1 and 2 of
Probability Estimates Used in the ModelTable 1 Probability Estimates Used in the Model
Parameter Diuretics ACEI ACEIBB ACEIBBAldA
Probability of death
per year for first
2 years
0.12 (6) 0.10 (6) 0.07 (7) 0.06 (8)
Probability of death
in year 3
0.13 (6) 0.13 (6) 0.13 (6) 0.13 (6)
Probability of death
in year 4 and
beyond
Factored in the additional mortality seen with increasing
age based on U.S. lifetime tables (14)
Health utility per
year lived
0.78 (19) 0.78 (19) 0.78 (19) 0.78 (19)
Probability of HF
hospitalization
per year
0.22 (6) 0.15 (6) 0.11 (7) 0.08 (8)
Values in parentheses are reference citation numbers.
ACEI  angiotensin-converting enzyme inhibitor; AldA  aldosterone antagonists; BB  beta-
blocker; HF  heart failure.he model. In all three treatment arms, we assumed that inear 3 and beyond, mortality rates were equal to those in the
iuretic-alone arm (Table 1).
ALYs. We assumed that quality of life did not differ
mong the cohorts, likely underestimating the positive
mpact of HFrEF medical therapy. We assumed that the
verage health utility was 0.78 based on a literature search of
ALY studies for patients with mild to moderate HF (19).
e multiplied this health utility by the percentage of
atients alive in each cohort to derive the average QALYs
or the cohort in each year of our model.
ensitivity analysis. We performed a sensitivity analysis
or ACEIBBAldA cohort compared to the diuretic and
CEIBB cohorts. We extended the mortality and hospi-
alization risk reductions in the treatment group to 5 and 15
ears. We also examined the impact of assuming the total
ost of care for the baseline group was 25% lower and
igher, the probability of death in the treatment group was
5% lower and higher, the probability of death in the
reatment group was 25% lower and 50% higher, the
robability of hospitalization in the treatment group was
0% lower and higher than the base case, and included
on-HF hospitalization costs. Annual non-HF hospitaliza-
ion costs were derived from the SOLVD trial (9). We
ssumed the annual non-HF hospitalization costs, $2,650
er year in 2012 dollars, remained constant over time. All
ife-years and costs were discounted at 3%, and costs were in
012 U.S. dollars. All analyses were performed using Excel
oftware (Microsoft, Redmond, Washington).
esults
ife expectancy. Outcomes are reported in Table 3. Dis-
ounted total life-years (and QALYs) in the diuretic-only
Costs EstimatesTable 2 Costs Estimates
All Arms
U.S. Dollars
in 2012 BB
U.S. Dollars
in 2012
Average cost of 1 HF
inpatient
hospitalization
10,146 (15) BB (per year) 48 (16)
Ambulatory care (per
year)
512 (9) Basic metabolic panel
(4 times a year the
first year)
49 (17)
Diuretics (per year) 48 (16) Basic metabolic panel
(3 times a year
after first year)
36 (17)
Basic metabolic panel
(3 times a year)
37 (17) 1 clinic visit after
initiating beta-
blocker (first year
only)
77 (17)
ACEI AldA
ACEI (per year) 48 (16) AldA (year) 48 (16)
Basic metabolic panel
(4 times a year the
first year)
49 (17) Basic metabolic panel
(6 times a year
first year)
73 (17)
Basic metabolic panel
(3 times a year
after first year)
37 (17) Basic metabolic panel
(3 times a year
after first year)
37 (17)Values in parenthesis are reference citation numbers.
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April 2, 2013:1440–6 Cost-Effectiveness of Heart Failure Medicationscohort were 4.45 years (3.47 QALYs). In the ACEI-treated
cohort, the total life-years (and QALYs) were 4.60 years
(3.59 QALYs); in the ACEIBB-treated cohort, they were
4.91 years (3.83 QALYs); and in the ACEIBBAldA
cohort, they were 5.01 years (3.90 QALYs).
Costs. Total costs are reported in Table 3. Over their
lifetime, patients in the diuretic-alone cohort accumulated
$12,742 (discounted at 3% per year) in healthcare costs.
Compared to the diuretic-treated cohort, cost savings in
those in the ACEI cohort were $444 and $33 in the
ACEIBB cohort. In the ACEIBBAldA cohort, there
was $47 in additional spending compared to the diuretics-
only cohort. There were no incremental cost-savings between
he ACEIBB versus the ACEI cohort or between the
CEIBBAldA versus ACEI BB cohort.
ost-effectiveness. The ACEI and ACEIBB treatments
ad lower costs and higher QALYs than the diuretic-only cohort.
he ICER of ACEIBBAldA versus ACEIBB was $501
nd $34 per life-year for the ACEIBBAldA versus
CEIBB cohort.
ospitalization rates. In the first 5 years of the model, the
umber of HF hospitalizations per 100 people was 110 for
he base cohort, 97 for the ACEI cohort, 88 for the
CEIBB cohort, and 82 for the ACEIBBAldA
ohort.
ensitivity analysis. We performed a sensitivity analysis of
he ACEIBBAldA cohort (Table 4). We first compared
he ACEIBBAldA with the diuretic-only cohort. We
ound that when we extended the reduction in mortality and
ospitalization in the treatment group to 5 years, the
CEIBBAldA cohort experienced better outcomes at
ower health care costs (strictly dominated the diuretic-only
ohort), and there was $356 in cost-savings; when benefits
ere extended to 15 years, ACEIBBAldA therapy no
onger provided a cost-savings but was highly cost-effective
ith an ICER of $623 per life-year ($799 per QALY).
hen the total cost in the ACEIBBAldA group in the
Estimated QALYs, Costs, and ICERTable 3 Estimated QALYs, Costs, and ICER
Parameter Diuretics
Total life-years 4
QALYs 3
Costs ($) 12,742
Incremental cost-effectiveness ratio (ICER) compared to diuretics
($ per life year)
NA
Sequential incremental cost-effectiveness ratio (ICER)
($/life-year; e.g., ACEIBBAldA vs. ACE  BB)
NA
Cost-savings compared to diuretics NA
Incremental cost-savings NA
5-year survival rate 0
Average cost per life-year ($) 2,862
Cost-savings per life-year lived ($) —
CHF hospitalizations over first 5 years per 100 people 110
Strictly dominated indicates the therapy was more effective and reduced healthcare costs (cost-s
ICER  incremental cost-effectiveness ratio; NA  not applicable; QALY  quality-adjusted liferst 2 years was 25% higher, the ICER was $1,363 per oife-year ($1,748 per QALY) compared to that in the
iuretic-only cohort; when the total cost was 25% lower in
he first 2 years, the treatment arm strictly dominated the
iuretic-only cohort, and there were cost-savings of $725.
hen probability of death in the ACEIBBAldA cohort
as 25% lower in the first 2 years, the ICER was $365 per
ife-year ($468 per QALY) compared to that in the
iuretic-only cohort; when the probability of death was 50%
igher in the first 2 years, the treatment arm strictly
ominated the diuretic-only cohort with a cost-savings of
738. When the probability of hospitalization in the
CEIBBAldA cohort was 50% higher in the first 2
ears, the ICER was $1,411 per life-year ($1,809 per
ALY) compared to the diuretic-only cohort; when the
robability of hospitalization was 50% lower in the first 2
ears, the treatment arm strictly dominated the diuretic-
nly cohort, with a cost-savings of $756. When the cost of
on-HF hospitalizations was included, the ICER of
CEIBBAldA versus diuretic-only cohort was $2,677
er life-year ($3,431 per QALY). An additional sensitivity
nalysis for ACEIBBAldA versus ACEIBB is pre-
ented in Table 4.
iscussion
he goal of this study was to quantify incremental cost-
ffectiveness of guideline-directed medical therapies for
FrEF. Our study demonstrates that not only is medical
herapy of HFrEF with ACEIBBAldA cost-effective,
ut also that treatment with ACEI and BB is cost-saving
ompared to treatment with diuretics alone. Previous cost-
ffectiveness analyses showed that medical therapy in pa-
ients with mild or moderate HFrEF was very cost-effective
$100 to $25,000 per life-year) or cost-neutral (9–13). To
he best of our knowledge, this is the first lifetime cost-
ffectiveness analysis to show cost-savings with medical
herapy in patients with mild to moderate HFrEF. Only
ACEI ACEIBB ACEIBBAldA
4.60 4.91 5.01
3.59 3.83 3.90
12,298 12,709 12,756
Strictly dominated Strictly dominated 34
Strictly dominated 1,323 501
444 33 —
444 — —
0.51 0.54 0.56
2,674 2,588 2,548
188 273 313
97 88 82
ther abbreviations as in Table 1.Alone
.45
.47
.49ne cost-effectiveness analysis in patients with severe HF
u
c
$
m
p
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those taking ACEI (20).
Costs in our model were sensitive to effects of probability
of death, hospitalization, total costs, and length of HF
treatment’s risk reduction on mortality and hospitalization.
In the treatment groups, net cost was a balance between
increased costs from more accrued costs from additional
life-years lived and decreased costs from reduced hospital-
ization. The ACEI cohort and the cohort in the sensitivity
analysis with higher mortality rates had more cost-savings
than the base case ACEIBBAldA cohort compared to
the diuretics-alone cohort because of the costs associated
with additional life-years lived.
Many of our assumptions were conservative with regard
to the impact of medical therapy on HF. We may have
underestimated the positive impact on QALYs because we
were unable to factor in the quality-of-life benefit of HF
treatment associated with decreased hospitalizations and
increased functional status. However, there may have been
some adverse effects of the treatments on quality of life that
we did not capture. We were unable to quantify long-term
gains from HF treatment because there are no long-term
studies of mortality or hospitalization reductions of HF
treatment. We also did not factor in the reduction in
indirect costs associated with decreased mortality and mor-
bidity with medical therapy; the lost productivity due to
early mortality of HF is estimated to be above 4 billion
dollars a year in the United States (5). We also assumed
that there was complete adherence to HF medical ther-
apies in the representative studies. However, even large
Sensitivity Analysis for ACEIBBAldATable 4 Sensitivity Analysis for ACEIBBAldA
Parameter
ACEIBBAldA vs. Diure
ICER
($/Life-Year Gained)
ICER
($/QALY Gai
15 years of HF treatment benefits 623 799
5 years of HF treatment benefits Strictly dominated Strictly domin
Total cost 25% higher in
ACEIBBAldA cohort
(first 2 years only)
1,363 1,748
Total cost 25% lower
ACEIBBAldA cohort
(first 2 years only)
Strictly dominated Strictly domin
Probability of death 25% lower in
the ACEIBBAldA cohort
(first 2 years only)
365 468
Probability of death 50% higher
ACEIBBAldA cohort
(first 2 years only)
Strictly dominated Strictly domin
Probability of hospitalization 50%
lower in ACEIBBAldA cohort
(first 2 years only)
1,411 1,809
Probability of hospitalization 50%
higher in ACEIBBAldA
cohort (first 2 years only)
Strictly dominated Strictly domin
Including costs of non-HF
hospitalizations
2677 3431
Abbreviations as in Tables 1 and 2.randomized studies have had up to 25% nonadherence irates to HF medical therapies (21). This suggests that the
treatment effects of guideline-directed HF medical ther-
apies could potentially be even greater than that reported
in clinical trials with more effective strategies to ensure
adherence.
Even in the most unfavorable situation, cost-effectiveness
ratios for each of the guideline-directed mediations for
HFrEF compare very favorably to estimates for other
generally accepted medical therapies, such as dialysis. For
example, some believe that Medicare coverage of patients
with chronic renal failure requiring dialysis, which has an
estimated cost-effectiveness of $50,000 or more per
QALY, implies a societal judgment that treatments with
a lower cost/QALY ratio are cost-effective and should be
provided (22).
This low cost of treatment and possible cost-savings is an
important finding because it suggests that further invest-
ment should be made to ensure systems such as HF disease
management programs are in place to optimally implement
guideline-directed medical therapies and facilitate patients
adhering to the prescribed regimen (23–25). If a hypothetical
program was 100% effective at ensuring all guideline-appropriate
patients were receiving ACEIBBAldA, $13,986 could be
spent per patient on such a program and maintain an ICER of
$25,000 per life-year for ACEIBBAldA therapy versus di-
retics alone. If this program was only 20% effective, $2,786
ould still be spent per patient and maintain an ICER of
25,000 per life-year. This suggests that significant invest-
ents in HF treatment can be cost-effective. One such
rogram is Get With The Guidelines, which has shown
ACEIBBAldA vs. ACEIBB
Cost-
Savings
ICER
($/Life-Year Gained)
ICER
($/QALY Gained)
Cost-
Savings
— 712 912 —
356 Strictly dominated Strictly dominated 323
— 8,255 10,583 —
725 Strictly dominated Strictly dominated 692
— 1,194 1,531 —
738 3,695 4,737 —
— Strictly dominated Strictly dominated 722
756 712 912 —
— 3151 4,039 —tics
ned)
ated
ated
ated
atedncreased adherence to guideline-directed medical therapies
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hospitals, and performance recognition (26,27).
The direct costs of medical treatment of HF have been
significantly reduced since ACEI, BB, and AldA all have
generic versions; this in itself may increase adherence.
Studies have shown that even a $10 increase in copayments
for BB resulted in almost a 2% decrease in adherence and a
9% increase in risk of hospitalization; similar results were
also found with price changes of ACEI (28). The MI
FREEE (Post-Myocardial Infarction Free Rx Event and
Economic Evaluation) trial demonstrated that the elimina-
tion of copayments for medications prescribed after myo-
cardial infarction improved medication adherences, reduced
rates of first major vascular events, and decreased patient
spending without increasing overall health costs (29). Given
the very high healthcare value provided by guideline-
directed medical therapies for HFrEF, eliminating all pa-
tient costs for these medications or even providing financial
incentives to promote adherence is likely to be advantageous
to patients, healthcare delivery systems, and society, al-
though these benefits may not be equally shared.
Study limitations. Limitations exist with any modeling
process that simplifies reality by assumptions. We assumed
that the therapies reduce rates of mortality and hospitaliza-
tion by the same proportion as observed in clinical trials.
This assumption about efficacy is commonly made in
cost-effectiveness studies. We were also unable to model the
increasing costs at the end of life, but assumed that the cost
at the end of life in the treatment cohorts would be the same
as the diuretics alone cohort. The costs used in this study are
only estimates of true costs. While hospitalization costs
were derived using charges and cost-to-charge ratios, this
approach may not accurately reflect true costs. Further, this
analysis integrated different perspectives in determining
costs/cost-savings and did not account for indirect costs.
We also did not include the cost of non-HF hospitalizations
in our base-case analysis because we considered this cost to
be unrelated to the interventions studied. We adopted the
view of Garber and Phelps and Lee that future costs
unrelated to the interventions studied can be excluded from
cost-effectiveness models (30,31). There was no change in
non-HF hospitalization rates with medical treatment of
HFrEF in the SOLVD, MERIT-HF, EMPHASIS-HF,
or other trial, to our knowledge (6–8). Nevertheless, we
included the cost of non-HF hospitalizations in our sensi-
tivity analysis and found that HF treatment was still highly
cost-effective.
At the same time, we undertook several conservative
measures that strengthen the confidence in our findings. We
did not include quality of life in effectiveness, even though
quality of life seems to benefit from these medications. Also,
the costs of outpatient HF care are assumed to be constant.
One difficulty in estimating incremental treatment effective-
ness and population risk is that “background HF care,” (i.e.,
care other than ACEI, BB, and AldA therapy) is often
poorly defined in available trials. We chose background careto be the placebo arm in the SOLVD trial. Since its
publication more than a decade ago, some may argue that
background HF care (e.g., use of diuretics, digoxin, diet) has
changed, which may decrease the rate of hospitalizations.
Despite this limitation, the SOLVD trial remains the best
source of data on the long-term risks of hospitalization and
death for HFrEF patients.
Conclusions
This analysis offers broad insight into the incremental cost-
effectiveness of guideline-directed medical therapies for HFrEF.
Use of ACEI, ACEIBB, and ACEIBBAldA therapies
were associated with significant health gains and were cost-saving
or highly cost-effective, with greatest gains in QALY occurring
when all three medications were provided. Even under the
most unfavorable assumptions, these guideline-directed med-
ical therapies remained highly cost-effective with cost per
QALY $10,000. Our study also suggests that $3,000 to
$14,000 per patient could be spent to ensure adherence to these
therapies and still maintain an attractive ICER of $25,000 per
life-year gained. Further resources should be allocated to
ensure full adherence to guideline-directed medical therapies
for HFrEF to improve outcomes, provide high-value care, and
minimize health care costs.
Reprint requests and correspondence: Dr. Gregg C. Fonarow,
Ahmanson-UCLA Cardiomyopathy Center, 10833 LeConte Av-
enue, Room A2-123 CHS, Los Angeles, California 90095-1679.
E-mail: gfonarow@mednet.ucla.edu.
REFERENCES
1. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007–18.
2. Lloyd-Jones DM, Larson MG, Leip EP et al. Lifetime risk for
developing congestive heart failure: the Framingham Heart Study.
Circulation 2002;106:3068–72.
3. Loehr LR, Rosamond WD, Chang PP, Folsom AR, Chambless LE.
Heart failure incidence and survival (from the atherosclerosis risk in
communities study). Am J Cardiol 2008;101:1016–22.
4. Askoxylakis V, Thieke C, Pleger ST et al. Long-term survival of
cancer patients compared to heart failure and stroke: a systematic
review. BMC Cancer 2010;10:105.
5. Lloyd-Jones D, Adams RJ, Brown TM et al. Heart disease and stroke
statistics–2010 update: a report from the American Heart Association.
Circulation 2010;121:e46–e215.
6. SOLVD Investigators. Effect of enalapril on survival in patients with
reduced left ventricular ejection fractions and congestive heart failure.
N Engl J Med 1991;325:293–302.
7. Hjalmarson A, Goldstein S, Fagerberg B et al. Effects of controlled-
release metoprolol on total mortality, hospitalizations, and well-being in
patients with heart failure: the metoprolol Cr/Xl randomized intervention
trial in congestive heart failure. JAMA 2000;283:1295–302.
8. Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with
systolic heart failure and mild symptoms. N Engl J Med 2011;364:
11–21.
9. Glick H, Cook J, Kinosian B et al. Costs and effects of enalapril
therapy in patients with symptomatic heart failure: an economic
analysis of the studies of left ventricular dysfunction treatment trial.
J Card Fail 1995;1:371–80.
10. McKenna C, Burch J, Suekarran S et al. A systematic review and
economic evaluation of the clinical effectiveness and cost-effectiveness
of aldosterone antagonists for postmyocardial infarction heart failure.
Health Technol Assess 2010;14:1–162.
11
1
2
2
2
2
2
2
2
2
2
2
3
3
1446 Banka et al. JACC Vol. 61, No. 13, 2013
Cost-Effectiveness of Heart Failure Medications April 2, 2013:1440–611. Levy AR, Briggs AH, Demers C, O’Brien BJ. Cost-effectiveness of
beta-blocker therapy with metoprolol or with carvedilol for treatment
of heart failure in Canada. Am Heart J 2001;142:537–43.
12. Goehler A, Geisler BP, Manne JM et al. Decision-analytic models to
simulate health outcomes and costs in heart failure: a systematic
review. Pharmacoeconomics 2011;29:753–69.
13. Gregory D, Udelson JE, Konstam MA. Economic impact of beta
blockade in heart failure. Am J Med 2001;110:74S–80S.
14. Arias E. United States life tables, 2007. National vital statistics reports.
Hyattsville, MD: Centers for Disease Control and Prevention; Na-
tional Center for Health Statistics 2011;59:1–60.
15. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost
effectiveness of carvedilol for heart Failure. Am J Cardiol 1999;83:
890–6.
16. Walmart [website]. Available at: http://www.walmart.Com/
Index.Gsp. Accessed January 8, 2013.
7. Centers for Medicare and Medicaid Services [website]. Available at:
http://www.cms.Gov. Accessed January 8, 2013.
8. Bureau of Labor Statistics, US Department of Labor. Consumer price
index inflation calculator. Available at: http://www.bls.gov/data/
inflation_calculator.htm. Accessed January 8, 2013.
9. Dyer MT, Goldsmith KA, Sharples LS, Buxton MJ. A review of
health utilities using the Eq-5d in studies of cardiovascular disease.
Health Qual Life Outcomes 2010;8:13.
0. Glick HA, Orzol SM, Tooley JF, Remme WJ, Sasayama S, Pitt B.
Economic evaluation of the randomized aldactone evaluation study:
treatment of patients with severe heart failure. Cardiovasc Drugs Ther
2002;16:53–9.
1. Ekman I, Andersson G, Boman K et al. Adherence and perception of
medication in patients with chronic heart failure during a five-year
randomised trial. Patient Educ Couns 2006;61:348–53.2. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG.
Willingness to pay for a quality-adjusted life year: in search of a
standard. Med Decis Making 2000;20:332–42.
3. Chan DC, Heidenreich PA, Weinstein MC, Fonarow GC. Heart
failure disease management programs: a cost-effectiveness analysis. Am
Heart J 2008;155:332–8.
4. Astrup A, Dyerberg J, Elwood P et al. The role of reducing intakes of
saturated fat in the prevention of cardiovascular disease: where does the
evidence stand in 2010? Am J Clin Nutr 2011;93:684–8.
5. Whellan DJ, Hasselblad V, Peterson E, O’Connor CM, Schulman
KA. Metaanalysis and review of heart failure disease management
randomized controlled clinical trials. Am Heart J 2005;149:722–9.
6. LaBresh KA, Fonarow GC, Smith SC Jr et al. Improved treatment of
hospitalized coronary artery disease patients with the get with the
guidelines program. Crit Pathw Cardiol 2007;6:98–105.
7. Xian Y, Pan W, Peterson ED et al. Are quality improvements
associated with the get with the guidelines-coronary artery disease
program sustained over time? A longitudinal comparison of GWTG-
CAD hospitals versus non-GWTG-CAD hospitals. Am Heart J
2010;159:207–14.
8. Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment
and adherence in chronic heart failure: effect on cost and outcomes.
Pharmacotherapy 2006;26:1157–64.
9. Choudhry NK, Avorn J, Glynn RJ et al. Full coverage for preventive
medications after myocardial infarction. N Engl J Med 2011;365:
2088–97.
0. Garber AM, Phelps CE. Economic foundations of cost-effectiveness
analysis. J Health Econ 1997;16:1–31.
1. Lee RH. Future costs in cost effectiveness analysis. J Health Econ
2008;27:809–18.Key Words: cost-effectiveness y heart failure y medications.
